Robert J. Heine, M.D., Ph.D., F.R.C.P., will join Eli Lilly and Co. in January, 2008, as executive medical director for the diabetes and endocrine division responsible for development of Lilly’s expanding diabetes and obesity R&D portfolio. Dr. Heine replaces Dr. Meng Hee Tan, who will retire at the end of September after 8 years of service to the company. “Lilly has a growing and exciting diabetes and obesity R&D portfolio that demands exceptional clinical leadership to guide an...